Pharmaceutical companies Moderna and Merck have announced positive Phase 3 trial results for intismeran, a personalized mRNA vaccine that reduces melanoma relapse and death.
The clinical trial evaluated the combination of the experimental therapy, also known as vaccine 940 or intismeran autogen, alongside the immunotherapy drug Keytruda, known generically as pembrolizumab. Data from the study showed that combining the two treatments yielded favorable results in overall patient survival while significantly lowering the risk of the cancer metastasizing to other organs.
Melanoma is widely recognized as one of the most aggressive forms of skin cancer. Although surgical intervention to remove tumors is standard practice, patients often face a substantial risk of disease recurrence, making post-operative adjuvant therapies critical to long-term survival.
Custom genetic design
A primary feature of the new treatment is its fully customized approach tailored to the biological characteristics of individual tumors. The manufacturing process begins with the extraction and genetic analysis of a patient's tumor sample following surgery. Scientists then design a specific dose of messenger RNA based on the unique mutational genetic footprint of that specific tumor.
Once administered, the mRNA vaccine instructs the patient's immune system to identify the precise markers of the cancerous cells. This specialized training enables the immune system to mount a targeted defense, substantially reducing the likelihood of the disease returning.
Messenger RNA technology first achieved widespread global recognition during the COVID-19 pandemic, when Moderna emerged as a key developer of mRNA vaccines. Researchers have since sought to apply the same genetic delivery mechanism to oncology, training the body to identify and eliminate cancer cells.
Clinical trial structure
The late-stage study, designated as the Interpath-001 trial, enrolled 1,137 participants diagnosed with various stages of melanoma. Every patient in the study had previously undergone surgery to remove their primary skin tumors prior to receiving treatment.
Investigators structured the trial to evaluate the added benefit of the personalized vaccine against standard therapy. One-third of the participants received pembrolizumab alone, which serves as an established checkpoint inhibitor immunotherapy. The remaining two-thirds of participants were treated with a combination of pembrolizumab and the intismeran vaccine.
Georgina Long, the principal investigator for the Interpath-001 study, described the findings as a landmark moment in skin cancer care. She explained that the results represent a major milestone for the adjuvant treatment of melanoma.
Long noted that Interpath-001 is the first Phase 3 trial to demonstrate that intismeran, when tailored to a patient's mutational profile and combined with pembrolizumab, can successfully decrease the risk of cancer recurrence or patient mortality.
Expansion and market response
Moderna and Merck confirmed that they plan to present the complete dataset from the Interpath-001 trial at an upcoming international medical conference.
The success in melanoma has prompted researchers to expand the scope of the clinical program. The broader Interpath clinical initiative is currently conducting trials to test mRNA vaccine combinations in other solid tumors, including lung cancer, bladder cancer, and renal cell carcinoma.
The announcement triggered a strong positive reaction on financial markets, driving a rise in Moderna shares as investors reacted to the clinical progress. Medical experts view the data as a promising development in precision oncology, offering a new pathway for tailored cancer therapies.
